Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Harland

PMS48 Tocilizumab in Methotrexate-Intolerant or Contraindicated Patients – A Cost-Utility Model for the UK

Value in Health

English

Related publications

FRI0313 the Efficacy and Safety of Tocilizumab Therapy in Patients With Polymyalgia Rheumatica Who Were Resistant or Intolerant to Glucocorticoids and Additional Methotrexate

2017

English

Mean Cost Per Number Needed to Treat With Tocilizumab Plus Methotrexate Versus Abatacept Plus Methotrexate in the Treatment of Rheumatoid Arthritis in Patients Previously Treated With Methotrexate

ClinicoEconomics and Outcomes Research

English

Psy108 - Cost-Utility Analysis of Tocilizumab in Combination With Corticosteroids for the Treatment of Giant Cell Arteritis in Italian Patients

English

Pms56 - Cost-Effectiveness Analysis of Subcutaneous Tocilizumab Without Methotrexate in Rheumatoid Arthritis Treatment

English

Pms44 - Cost-Effectiveness Analysis of Subcutaneous Tocilizumab Plus Methotrexate in Rheumatoid Arthritis Treatment

English

A UK-based Cost-Utility Analysis of Radiofrequency Ablation or Oesophagectomy for the Management of High-Grade Dysplasia in Barrett’s Oesophagus

Alimentary Pharmacology and Therapeutics

English

Cost Effectiveness of Drug Eluting Coronary Artery Stenting in a UK Setting: Cost-Utility Study

Heart

Cardiovascular Medicine

Cardiology

2006

English

Peritoneal Dialysis and In-Centre Haemodialysis: A Cost-Utility Analysis From a UK Payer Perspective

Applied Health Economics and Health Policy

English

Pmu65 - Cost-Minimization Analysis of Smofkabiven® Central for Adult Patients With Impossible, Insufficient or Contraindicated Oral or Enteral Nutrition Versus Standard Endovascular Treatment in the Mexican Public Healthcare System

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by D. Harland

PMS48 Tocilizumab in Methotrexate-Intolerant or Contraindicated Patients – A Cost-Utility Model for the UK

Related publications

FRI0313 the Efficacy and Safety of Tocilizumab Therapy in Patients With Polymyalgia Rheumatica Who Were Resistant or Intolerant to Glucocorticoids and Additional Methotrexate

Mean Cost Per Number Needed to Treat With Tocilizumab Plus Methotrexate Versus Abatacept Plus Methotrexate in the Treatment of Rheumatoid Arthritis in Patients Previously Treated With Methotrexate

Psy108 - Cost-Utility Analysis of Tocilizumab in Combination With Corticosteroids for the Treatment of Giant Cell Arteritis in Italian Patients

Pms56 - Cost-Effectiveness Analysis of Subcutaneous Tocilizumab Without Methotrexate in Rheumatoid Arthritis Treatment

Pms44 - Cost-Effectiveness Analysis of Subcutaneous Tocilizumab Plus Methotrexate in Rheumatoid Arthritis Treatment

A UK-based Cost-Utility Analysis of Radiofrequency Ablation or Oesophagectomy for the Management of High-Grade Dysplasia in Barrett’s Oesophagus

Cost Effectiveness of Drug Eluting Coronary Artery Stenting in a UK Setting: Cost-Utility Study

Peritoneal Dialysis and In-Centre Haemodialysis: A Cost-Utility Analysis From a UK Payer Perspective

Pmu65 - Cost-Minimization Analysis of Smofkabiven® Central for Adult Patients With Impossible, Insufficient or Contraindicated Oral or Enteral Nutrition Versus Standard Endovascular Treatment in the Mexican Public Healthcare System